Zollinger‑Ellison Secondary Ulcer Disease
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, which in turn creates secondary peptic ulcers that are often multiple, recurrent, and resistant to standard ulcer therapy. Although the primary condition is the gastrinoma, the term “Zollinger‑Ellison secondary ulcer disease” is used to emphasize the ulcer complications that arise from the underlying endocrine tumor.
Who it affects: ZES can occur at any age but most commonly presents in the 4th to 6th decade of life. Men and women are affected equally. About 25 % of patients have an inherited form (multiple endocrine neoplasia type 1, MEN 1) while the remaining 75 % have sporadic gastrinomas.[1] Mayo Clinic
Prevalence: Gastrinomas are rare, with an estimated incidence of 0.5–2 cases per million people per year. Because many patients develop ulcers before the tumor is discovered, ZES accounts for less than 1 % of all peptic ulcer disease cases.[2] NIH
Symptoms
Symptoms arise from two mechanisms: excessive gastric acid and the mass effect of the tumor (if large). The classic triad includes abdominal pain, refractory ulcers, and diarrhoea.
- Epigastric or upper‑abdominal pain – Often described as burning or gnawing; worsens 1–3 hours after meals when acid secretion peaks.
- Recurrent or multiple peptic ulcers – Can be located in the duodenum, jejunum, or even the esophagus; ulcers may fail to heal with standard proton‑pump inhibitor (PPI) therapy.
- Diarrhoea – Occurs in up to 80 % of patients; caused by acid‑induced secretory diarrhoea and malabsorption.
- Steatorrhea (fatty stools) – Due to pancreatic enzyme inactivation by acid.
- Nausea & vomiting – May be related to ulcer perforation or gastric outlet obstruction.
- Weight loss – Result of malabsorption, chronic diarrhoea, and decreased intake because of pain.
- Gastro‑oesophageal reflux (GERD) symptoms – Heartburn, regurgitation, and sour taste.
- Gastric or duodenal bleeding – Presents as melena, hematemesis, or iron‑deficiency anaemia.
- Perforation or obstruction signs – Sudden severe abdominal pain, rigid abdomen, or vomiting of bile‑stained fluid.
- Symptoms related to the tumor itself – If the gastrinoma is large, patients may feel a palpable abdominal mass or experience vague “fullness” after eating.
Causes and Risk Factors
Primary cause – Gastrin‑producing neuroendocrine tumor
Gastrinomas arise from enterochromaffin‑like (ECL) cells in the pancreas (most common) or duodenum. They secrete gastrin autonomously, bypassing normal feedback inhibition.
Risk factors
- Multiple endocrine neoplasia type 1 (MEN 1) – Inherited mutation in the MEN1 gene; up to 20‑30 % of ZES patients have MEN 1.
- Family history of gastrinomas or MEN 1 – Genetic counseling is advised for first‑degree relatives.
- Age – Incidence rises after age 30, peaks in the 50s.
- Chronic H. pylori infection – While it does not cause ZES, co‑existing infection can worsen ulcer disease.
- Smoking – Associated with increased gastrinoma growth and more severe ulcer disease.
Diagnosis
Because symptoms overlap with common ulcer disease, a high index of suspicion is needed, especially when ulcers are refractory, multiple, or located distal to the duodenum.
Laboratory tests
- Fasting serum gastrin – Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive. Levels > 150 pg/mL together with a gastric pH < 2 is diagnostic.
- Secretin stimulation test – Administration of secretin paradoxically raises gastrin in ZES; a rise ≥ 120 pg/mL confirms diagnosis.
- Chromogranin A – Elevated in many neuroendocrine tumors, used for monitoring.
Imaging studies
- Endoscopic ultrasound (EUS) – Excellent for detecting small pancreatic or duodenal gastrinomas.
- Multiphasic contrast‑enhanced CT or MRI – Provides an anatomic map of the primary tumor and metastases (commonly to the liver).
- Somatostatin receptor scintigraphy (Octreotide scan) or 68Ga‑DOTATATE PET/CT – Highly sensitive for neuroendocrine tumor localization.
- Upper endoscopy (EGD) – Visualises the ulcers, obtains biopsies to rule out malignant ulceration, and assesses for bleeding.
Histopathology
When a tumor is resected, pathology confirms a well‑differentiated neuroendocrine tumor (NET) with immunohistochemical staining for gastrin and synaptophysin.
Treatment Options
Effective management requires two parallel strategies: acid suppression to heal ulcers and tumor control to stop gastrin overproduction.
Acid‑suppression therapy
- High‑dose Proton Pump Inhibitors (PPIs) – Omeprazole 40‑80 mg daily, or equivalent (e.g., esomeprazole 40‑80 mg). Doses can be titrated to achieve gastric pH > 4.
- H2‑receptor antagonists – Usually insufficient as monotherapy but may be added for breakthrough symptoms.
- Potassium‑competitive acid blockers (PCABs) – Newer agents such as vonoprazan (available in some countries) provide rapid, sustained acid control.
Tumor‑directed therapy
- Surgical resection – Preferred curative approach for localized gastrinomas. Enucleation or pancreaticoduodenectomy may be performed depending on size and location.
- Somatostatin analogues – Octreotide or lanreotide suppress gastrin release and can shrink tumors; often first‑line for metastatic disease.
- Targeted therapy – Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, unresectable NETs.
- Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves symptom control and progression‑free survival.
- Chemo‑embolization or radio‑frequency ablation – Locoregional treatments for liver metastases.
- Cytotoxic chemotherapy – Reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑based combinations.
Lifestyle & supportive measures
- Dietary adjustments – Small, low‑fat meals; avoid alcohol, caffeine, and very spicy foods that can aggravate acid secretion.
- Smoking cessation – Reduces ulcer recurrence and may slow tumor growth.
- Vitamin B12 and iron supplementation – Needed if chronic bleeding or malabsorption occurs.
- Bone health monitoring – Long‑term PPIs may affect calcium absorption; DEXA scanning is advised for patients on high‑dose PPIs > 5 years.
Living with Zollinger‑Ellison Secondary Ulcer Disease
Daily medication management
- Take PPIs at the same time each day, preferably 30 minutes before the first meal.
- Keep a medication log; note any breakthrough pain that may require dose adjustment.
- Schedule regular follow‑up labs (gastrin, chromogranin A, CBC, electrolytes) every 3–6 months.
Dietary tips
- Eat 5–6 small meals per day to avoid large acid spikes.
- Choose low‑acid foods (bananas, oatmeal, rice, lean poultry).
- Limit citrus, tomato products, chocolate, peppermint, and carbonated beverages.
- Stay hydrated; aim for 2‑3 L of water daily unless fluid restriction is advised for heart/kidney disease.
Monitoring for complications
- Track stool frequency and consistency; new onset of black, tarry stools or sudden increase in diarrhoea warrants prompt evaluation.
- Record any new abdominal tenderness, fever, or vomiting.
- Perform self‑breath tests for H. pylori if recommended by your physician, as eradication can improve ulcer healing.
Psychosocial support
Living with a chronic rare disease can be stressful. Consider joining patient‑support groups (e.g., NET Disease Patient Foundation), seeking counseling, and maintaining open communication with your health‑care team.
Prevention
Because the primary gastrinoma is not preventable, “prevention” focuses on minimizing ulcer complications.
- Adhere strictly to prescribed high‑dose PPI therapy.
- Avoid NSAIDs, aspirin, and other ulcer‑causing medications unless specifically instructed by a physician.
- Eradicate H. pylori infection if present – this reduces additive ulcer risk.
- Maintain a healthy weight and limit alcohol intake (≤ 1 drink/day for women, ≤ 2 drinks/day for men).
- Enroll in regular surveillance imaging (CT/MRI every 6–12 months) to detect tumor progression early.
Complications
If untreated or inadequately controlled, secondary ulcer disease can lead to serious outcomes:
- Ulcer perforation – Can cause peritonitis, sepsis, and requires emergency surgery.
- Gastrointestinal bleeding – May lead to anemia, transfusion dependence, or hypovolemic shock.
- Gastric outlet obstruction – Caused by edema or scarring; manifests as persistent vomiting.
- Malabsorption & nutritional deficiencies – Fat‑soluble vitamin (A, D, E, K) and mineral deficiencies due to acid‑inactivated pancreatic enzymes.
- Metastatic gastrinoma – Liver is the most common site; can cause hepatic dysfunction and further acid‑related symptoms.
- Refractory diarrhoea and electrolyte loss – Leads to dehydration, hypokalemia, and renal impairment.
- Secondary peptic‑stricture formation – Narrowing of the duodenum or jejunum requiring dilation or surgery.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve with analgesics.
- Vomiting of blood (hematemesis) or material that looks like coffee grounds.
- Black, tarry stools (melena) or bright red blood per rectum.
- Fever > 38 °C (100.4 °F) combined with abdominal tenderness.
- Rapid heart rate (> 120 bpm), low blood pressure, or dizziness indicating possible shock.
- Sudden inability to pass gas or stool (possible bowel obstruction).
- Severe, persistent diarrhoea leading to dehydration (dry mouth, decreased urine output).